Capabilities
Engineering clinically viable drug products through integrated formulation science, predictive modelling, and translational development strategy.
We work at the intersection of molecular complexity, formulation engineering, and clinical translation
—helping transform high-risk molecules into executable, development-ready programmes.
Translating Molecule Complexity into Clinical Reality
Most molecules fail not due to lack of efficacy—but because they cannot achieve consistent, clinically relevant exposure or scalable manufacturability.
Our approach integrates molecular engineering, predictive biopharmaceutics, and formulation science into a unified development pathway—designed to reduce uncertainty, minimise rework, and accelerate clinical readiness.
Core Capabilities
A structured, end-to-end development framework
spanning molecular design to clinical execution.
- Solid-state characterisation (polymorphism, salt forms)
- Biopharmaceutic profiling and developability assessment
- Early risk identification for stability and manufacturability
- Lipid-based systems and amorphous dispersions
- Injectable, oral, and transdermal systems
- Stability and exposure optimisation strategies
- Nanoemulsions and carrier-based systems
- Controlled and sustained release architectures
- Tissue and site-specific targeting strategies
- PBPK modelling and simulation
- IVIVC development and validation
- Dose prediction and exposure optimisation
- Aligning preclinical data with clinical exposure targets
- Designing first-in-human strategies
- Reducing iteration cycles and development uncertainty
Molecule Rescue & Repositioning
Not all molecules fail due to lack of therapeutic potential—many fail due to formulation, exposure, or development strategy limitations.
We identify the root causes of failure and redesign development pathways to unlock clinical viability.
What We Do
- Diagnose failure drivers (solubility, variability, PK mismatch)
- Redesign formulations and delivery strategies
- Reposition assets through exposure optimisation
- Rebuild development pathways aligned to clinical endpoints
When It Matters
- Stalled or discontinued programmes
- Molecules with poor or inconsistent bioavailability
- Repeated clinical or formulation failures
- Assets requiring differentiation or lifecycle extension
Revived development programmes with improved exposure, reduced variability, and a clearer path to clinical success.
Development Pathway
Data Foundation
Aggregating molecular, preclinical, and formulation data to define constraints and opportunities.
Predictive Modelling
Simulating pharmacokinetics, exposure, and formulation behaviour.
Strategy Design
Aligning formulation, PK targets, and clinical objectives.
Execution
Delivering development-ready programmes with clear regulatory and manufacturing pathways.
Where We Add the Most Value
- Early-stage uncertainty in formulation or PK
- Poor solubility or inconsistent exposure
- Transition from discovery to development
- First-in-human planning challenges
- Scale-up or manufacturing readiness issues
- Stalled or failing programmes
What Differentiates Our Approach
Integrated Thinking
Not isolated services—but a connected development pathway.
Prediction-Led Development
Decisions guided by modelling and data—not trial-and-error.
Execution Focus
Designed for clinical and manufacturing success—not theoretical optimisation.
Ready to de-risk your development programme?
Whether you are solving formulation challenges, reducing clinical uncertainty, or rescuing a stalled asset—we help you make better decisions earlier.